ZEPBOUND : THE NEW WEIGHT LOSS MEDICATION The FDA has just published a news release regarding its approval of Zepbound (Tirzepatide) for weight management. Zepbound which contains the same medication as the previously released Mounjaro, is a weekly injectable medication for chronic weight management in adults with obesity, (body mass index of 30 or greater), […]
More
A comparison of two drugs used to treat type 2 diabetes found that tirzepatide (Mounjaro) was superior to semaglutide (Ozempic) at blood sugar control (glucose) and promoting weight loss. A meta-analysis of 22 randomized controlled trials were just presented at the annual meeting of the European Association for the Study of Diabetes in October. Of the 22 trials included […]
More
Polycystic Ovarian Syndrome (PCOS) is a condition of hormonal imbalance that is characterized by menstrual cycle irregularity, weight gain, fertility problems, excessive hair growth, and acne. There are also metabolic factors involved in PCOS such as insulin resistance, with its associated risk of pre-diabetes and diabetes. And these conditions impart a greater risk of cardiovascular disease. Because […]
More
Wegovy, Ozempic and Mounjaro Surging demand for drugmaker Novo Nordisk’s highly popular diabetes treatments Ozempic and Wegovy, now being used for weight loss, has created a major supply shortage that has left Americans empty handed. Lack of insurance coverage for these medications only exacerbates the difficulty of accessing these drugs for many who would want […]
More
Tirzepatide Tirzepatide (Mounjaro) ia a once weekly GIP (glocose-dependent insulinoptropic polypeptide0 receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide activates the body’s receptors for GIP and GLP-1, which are found in the brain in the areas that control appetite regulation. Thus, as a result, tirzepatide reduces food intake shown in multiple studies. It also impacts fat utilization and […]
More